表 2.7.4.2.1-3　治験中に発現した有害事象（CTCAE グレード）（02CLLⅢ試験）

CTC category symptom	BEN (N = 154)	CLB (N = 144)	Total (N = 298)
ALLERGY/IMMUNOLOGY	15 (9.7%)	7 (4.9%)	22 (7.4%)
AUDITORY/HEARING	0 (0.0%)	1 (0.7%)	1 (0.3%)
BLOOD/BONE MARROW	90 (58.4%)	52 (36.1%)	142 (47.7%)
Hemoglobin (NCI-WG Criteria)	38 (24.7%)	20 (13.9%)	58 (19.5%)
Leukocytes	30 (19.5%)	4 (2.8%)	34 (11.4%)
Lymphopenia	10 (6.5%)	0 (0.0%)	10 (3.4%)
Neutrophils (NCI-WG Criteria)	43 (27.9%)	23 (16.0%)	66 (22.1%)
Platelets (NCI-WG Criteria)	38 (24.7%)	29 (20.1%)	67 (22.5%)
CARDIOVASCULAR (ARRHYTHMIA)	1 (0.6%)	3 (2.1%)	4 (1.3%)
CARDIOVASCULAR (GENERAL)	16 (10.4%)	7 (4.9%)	23 (7.7%)
COAGULATION	0 (0.0%)	1 (0.7%)	1 (0.3%)
CONSTITUTIONAL SYMPTOMS	56 (36.4%)	33 (22.9%)	89 (29.9%)
DERMATOLOGY/SKIN	44 (28.6%)	24 (16.7%)	68 (22.8%)
ENDOCRINE	1 (0.6%)	3 (2.1%)	4 (1.3%)
GASTROINTESTINAL	49 (31.8%)	32 (22.2%)	81 (27.2%)
HEMORRHAGE	0 (0.0%)	1 (0.7%)	1 (0.3%)
HEPATIC	14 (9.1%)	11 (7.6%)	25 (8.4%)
INFECTION/FEBRILE NEUTROPENIA*	41 (26.6%)	18 (12.5%)	59 (19.8%)
METABOLIC/LABORATORY	24 (15.6%)	6 (4.2%)	30 (10.1%)
MUSCULOSKELETAL	7 (4.5%)	9 (6.3%)	16 (5.4%)
NEUROLOGY	14 (9.1%)	14 (9.7%)	28 (9.4%)
OCULAR/VISUAL	3 (1.9%)	0 (0.0%)	3 (1.0%)
PAIN	17 (11.0%)	14 (9.7%)	31 (10.4%)
PULMONARY	20 (13.0%)	18 (12.5%)	38 (12.8%)
RENAL/GENITOURINARY	13 (8.4%)	3 (2.1%)	16 (5.4%)
SEXUAL/REPRODUCTIVE FUNCTION	0 (0.0%)	1 (0.7%)	1 (0.3%)
SYNDROMES (Tumor lysis syndrome, alcohol abuses with increased liver enzymes)	2 (1.3%)	0 (0.0%)	2 (0.7%)

Infections listed in table 38 include also infections assgined to other CTC categories

BEN：本剤群、CLB：クロラムブシル群

引用：CSR Table 48